Nuvectis Reports Positive NXP200 Phase 1b Study Data
Nuvectis reported positive data from an NXP200 Phase 1b study, citing durable responses, including complete responses, in patients with BRAF V600-mutated recurrent or progressive gliomas.
Nuvectis reported positive data from an NXP200 Phase 1b study, citing durable responses, including complete responses, in patients with BRAF V600-mutated recurrent or progressive gliomas.